Abstract
The present decade has seen a reawakening of tuberculosis (TB) drug research and development (R&D), spurred on by an urgent need to stem the tide of the disease globally and develop new, more effective treatments against drugsensitive and resistant strains. As a result, there are now seven products in clinical development and the largest pipeline of early-stage projects and compounds in history. The primary goals of this resurgent activity are to shorten
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
